Novel Isoxazoles which Interact with Brain Cholinergic Channel Receptors Have Intrinsic Cognitive Enhancing and Anxiolytic Activities

Journal of Medicinal Chemistry

Volumn 37, Issue 8, 1994, Pages 1055-1059

  Garvey, David S ^a,b   Wasicak, James T ^a   Decker, Michael W ^a   Brioni, Jorge D ^a   Buckley, Michael J ^a   Sullivan, James P ^a   Carrera, George M ^a   Holladay, Mark W ^a   Arneric, Stephen P ^a   Williams, Michael ^a  

^a ABBOTT LABORATORIES   (United States)

^b Anti infective Research Division ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 3 METHYL 5 (2 PYRROLIDINYL)ISOXAZOLE; A 79814; A 81754; A 82695; CHOLINERGIC RECEPTOR; CYTISINE; ISOXAZOLE DERIVATIVE; NICOTINE DERIVATIVE; OXOTREMORINE; RECEPTOR SUBTYPE; SODIUM CHLORIDE; TRITIUM; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL MODEL; ANXIETY; BINDING AFFINITY; CHOLINERGIC SYSTEM; COGNITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LETTER; MOUSE; NEUROCHEMISTRY; NONHUMAN; RECEPTOR BINDING;

ALKALOIDS; ANIMAL; ANTI-ANXIETY AGENTS; BINDING SITES; BRAIN; BUNGAROTOXINS; COGNITION; ISOXAZOLES; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NICOTINE; RATS; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC; STEREOISOMERISM;

EID: 0028294034     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00034a002     Document Type: Article

References (51)

1. Sims, N. A.; Bowen, D. M.; Allen, S. J.; Smith, C. C. T.; Neary, D.; Thomas, D. J.; Davison, A. N. Presynaptic Dysfunction in Patients with Dementia. J. Neurochem. 1983, 40, 503-509.
2. Bowen, D. M.; Allen, S. J.; Benton, J. S.; Goodhardt, M. J.; Haan, E. A.; Palmer, A.M.; Sims, N. R.; Smith, C. C. T.; Spillane, J. A.; Esiri, M. M.; Neary, D.; Snowden, J. S.; Wilcoch, G. K.; Davison, A. N. Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease. J. Neurochem. 1983, 41, 266-272.
3. Norberg, A.; Adem, A.; Hardy, J.; Winblad, B. Change in Nicotinic Receptor Subtypes in Temporal Cortex of Alzheimer Brains. Neurosci. Lett. 1986, 86, 317-321.
4. Shimohama, S.; Taniguchi, T.; Fujiwara, M.; Kameyama, M. Changes in Nicotinic and Muscarinic Cholinergic Receptors in Alzheimer-Type Dementia. J. Neurochem. 1986, 46, 288-293
5. Flynn, D. D.; Mash, D. C. Characterization of L-[3H] Nicotine Binding in Human Cerebral Cortex: Comparison Between Alzheimer's Disease and the Normal. J. Neurochem. 1986, 46, 1948-1954.
6. Whitehouse, P. J.; Martino, A. M.; Antuono, P. G.; Lowenstein, P. R.; Coyle, J. T.; Price, D. L.; Kellar, K. J. Nicotinic Acetylcholine Binding Sites in Alzheimer's Disease. Brain Res. 1986, 371, 146-151.
7. Whitehouse, P. J.; Martino, A. M.; Wagster, M. V.; Price, D. L.; Mayeux, R.; Atach, J. R.; Kellar, K. J. Reductions in [3H] Nicotinic Acetylcholine Binding in Alzheimer's Disease and Parkinson's Disease: An Autoradiographic Study. Neurology 1988, 38, 720-723.
8. Perry, E. K. The Cholinergic Hypothesis-Ten Years On. Br. Med. Bull. 1986, 42, 63-69.
9. Bartus, R. T.; Dean, R. L.; Fisher, S. K. Cholinergic Treatment for Age-Related Memory Disturbances: Dead or Barely Coming of Age? In Treatment Development Strategies for Alzheimer's Disease; Crook, T., Bartus, R. T., Ferris, S., Gershon, S., Eds.; Mark Powley Assoc.: Madison, CT, 1986; pp 421-450
10. Coyle, J. T.; Price, D. L.; DeLong, M. R. Alzheimer's Disease: A Disorder of Cortical Cholinergic Inervation. Science 1983, 279, 1184-1190.
11. Bovet, D.; Bovet-Nitti, F.; Olivero, A. Effects of Nicotine on Avoidance Conditioning of Inbred Strains of Mice. Psychopharmacology 1966, 10, 1-5.
12. Evangelista, A. M.; Gattoni, R. C.; Izquierdo, I. Effect of Amphetamine, Nicotine, and Hexamethone on Performance of a Conditioned Response During Acquisition and Retention Trials. Pharmacology 1970, 3, 91-96.
13. Haroutunian, V.; Barnes, E.; Davies, K. L. Cholinergic Modulation of Memory in Rats. Psychopharmacology 1985, 87, 266-271.
14. Buccafusco, J.; Jackson, W. Beneficial Effects of Nicotine Administered Prior to a Delayed Matching-To-Sample Task in Young and Aged Monkeys. Neurobiol. Aging 1991, 12, 233-238.
15. Pomerleau, O. F.; Turk, D. C.; Fertig, J. B. The Effects of Cigarette Smoking on Pain and Anxiety. Addict. Behav. 1984, 9, 265-271.
16. Newhouse, P. A.; Sunderland, Y.; Tariot, P. N.; Blumhardt, C. L.; Weingartner, H.; Mellow, A. Intravenous Nicotine in Alzheimer's Disease: A Pilot Study. Psychopharmacology 1988, 95, 171-175
17. Sahakian, B.; Jones, G.; Levy, R.; Gray, J.; Warburton, D. The Effects of Nicotine on Attention, Information Processing, and Short-Term Memory in Patients with Dementia of the Alzheimer Type. Br. J. Psych. 1989, 154, 797-800.
18. Nordberg, A.; Winblad, B. Reduced Number of [3H] Nicotine and [3H] Acetylcholine Binding Sites in the Frontal Cortex of Alzheimer's Brains. Neurosci. Lett. 1986, 72, 115-119.
19. Rinne, J.; Myllykyla, T.; Lonnberg, P.; Marjamaki, P. A Post-Mortem Study of Brain Nicotinic Receptors in Parkinson and Alzheimer's Disease. Brain Res. 1991, 547, 167-170
20. Duijn, C. V.; Hofman, A. Relation Between Nicotine Intake and Alzheimer's Disease. Br. Med. J. 1991, 302, 1491-1494.
21. Schwartz, R. D.; Kellar, K. J. Nicotinic Cholinergic Receptor Binding Sites in the Brain: Regulation In Vivo. Science 1983, 220, 214-216.
22. Ksir, C., Hakan, R.; Hall, D.P., Jr.; Kellar, K. J. Exposure to Nicotine Enhances the Behavioral Stimulant Effect of Nicotine and Increases Binding of [3H] Acetylcholine to Nicotinic Receptors. Neuropharmacology 1985, 24, 527-531
23. Benwall, M. E. M.; Balfour, D. J. K.; Anderson, J. M. Evidence that Tobacco Smoking Increases the Density of (-) [3H] Nicotine Binding Sites in Human Brain. J. Neurochem. 1988, 50, 1243-1247.
24. Jason, A. M.; Fuxe, K.; Agnati, L. F.; Jasson, A.; Bjeklke, B.; Sundstrom, E.; Anderson, K.; Harfstrand, A.; Goldstein, M.; Owman, C. Protective Effects of Chronic Nicotine Treatment on Lesioned Nigrostriatal Dopamine Neurons in the Male Rat. Prog. Brain Res. 1989, 79, 257-265.
25. Owman, C.; Fuxe, K.; Jason, A. M.; Kahrstrom, J. Studies of Protective Actions of Nicotine on Neuronal and Vascular Functions in the Brain of Rats: Comparison Between Sympathetic Noradrenergic and Mesostriatal Dopaminergic Fiber System, and the Effect of a Dopamine Agonist. Prog. Brain Res. 1989, 79, 267-276.
26. Wormsley, K. G. Smoking and Duodenal Ulcer. Gastroenterology 1978, 75, 139-152.
27. Eastwood, G. L. The Role of Smoking in Peptic Ulcer Disease. J. Clin. Gastroenterol. 1988, 10, 519-523
28. Gebber, G. L. Neurogenic Basis for the Rise in Blood Pressure Evoked by Nicotine in the Cat. J. Pharmacol. Exp. Ther. 1969, 166, 255-263.
29. Larson, P. S.; Silvette, H. Tobacco: Experimental and Clinical Studies; Williams & Wilkins: Baltimore, 1968; Suppl. I.
30. Larson, P. S., Silvette, H. Tobacco: Experimental and Clinical Studies; Williams & Wilkins: Baltimore, 1975; Suppl. III.
31. Quick, C. R. G.; Cotton, L. T. The Measured Effect of Stopping Smoking on Intermittent Claudication. Br. J. Surg. 1982, 69, 524-526.
32. Lusby, R. J.; Bauminger, B.; Woodcock, J. P.; Skidmore, R.; Baird, R. N. Cigarette Smoking: Acute Main and Small Vessel Hemodynamic Responses In Patients with Arterial Disease. Am. J. Surg. 1981, 142, 169-173.
33. Deneris, E. S.; Connolly, J.; Rogers, S. W.; DuVoisin, R. Pharmacological and Functional Diversity of Neuronal Nicotinic Acetylcholine Receptors. Trends Pharmacol. Sci. 1991, 12, 34-40.
34. Sargent, P. B. The Diversity of Neuronal Nicotinic Acetylcholine Receptors. Annu. Rev. Neurosci. 1993, 16, 403-443.
35. Arneric, S. P.; Williams, M. Nicotinic Agonists in Alzheimer's Disease: Does The Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS Selective Cholinergic Channel Activators? In The Treatment of Neurodegenerativo Disorders and Cognitive Function: Disease; Capri: Italy, 1993; in press
36. Garvey, D. S.; Wasicak, J. T., Chung, J. Y.-L.; Shue, Y. K., Carrera, G. M.; May, P. D.; McKinney, M. M.; Anderson, D.; Cadman, E.; Vella-Rountree, L.; Nadzan, A. M.; Williams, M. Synthesis and In Vitro Characterization of Novel Amino Terminally Modified Oxotremorine Derivatives for Brain Muscarinic Receptors. J. Med. Chem. 1992, 35, 1550-1557
37. Corey, E. J.; Fuchs, P. L. A Synthetic Method for Formyl⟶Ethynyl Conversion. Tetrahedron Lett. 1972, 3769-3772.
38. Enna, S. J.; Synder, S. H. Properties of γ-amino butyric acid (GABA) Receptor Binding in Rat Brain Synaptic Membrane Fractions. Brain Res. 1975, 100, 81-97.
39. Pabreza, L. A.; Dhawan, S.; Kellar, K. J. [3H] Cytisine Binding to Nicotinic Cholinergic Receptors in Brain. Mol. Pharmacol. 1990, 39, 9-12
40. Marks, M. J.; Stitzel, A.; Romm, E.; Wehner, J. M.; Collins, A. C. Nicotinic Binding Sites in Rat and Mouse Brain: Comparison of Acetylcholine, Nicotine, and α-Bungarotoxin. Mol. Pharmacol. 1986, 30, 427-436.
41. Chaturvedi, V; Donnelly-Roberts, D.; Lentz, T. L. Effects of Mutations of Torpedo Acetylcholine Receptor α Subunit Residues 184-200 on α-Bungarotoxin Binding in a Recombinant Fusion Protein. Biochemistry 1993, 32, 9570-9576.
42. Birdsall, N. J. M.; Burgen, A. S. V.; Hulme, E. C. The Binding of Agonists to Brain Muscarinic Receptors. Mol. Pharmacol. 1978, 14, 723-736
43. Cheng, Y.-C; Prusoff, W. H. Relationship Between the Inhibition Constant (Ki) and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108
44. Brioni, J.; Arneric, S. P. Nicotinic Receptor Agonists Facilitate Retention of Avoidance Training: Participation of Dopaminergic Mechanisms. Behavioral Neural Biol. 1993, 59, 57-62
45. Lister, R. G. The Use of a Plus-Maze to Measure Anxiety in the Mouse. Psychopharmacology 1987, 92, 180-185.
46. Brioni, J.; O'Neil, A. B.; Kin, D. J. B.; Decker, M. W. Nicotinic Receptor Agonists Exibit Anxiolytic-like Effects on the Elevated Plus Maze. Eur. J. Pharmacol. 1993, 238, 1-8.
47. Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B.; Kellar, K. J. A Subtype of Nicotinic Cholinergic Receptor is Composed of α4 and β2Subunits and is Upregulated by Chronic Nicotine Treatment. Mol. Pharmacol. 1992, 41, 31-37
48. Whiting, P.; Schoepfer, R.; Lindstrom, J.; Priestly, T. Structural and Pharmacological Characterization of the Major Brain Nicotinic Acetylcholine Receptor Subtype Stably Expressed in Mouse Fibroblasts. Mol. Pharmacol. 1992, 40, 463-472
49. Zhang, X.; Nordberg, A. The Competition of (—)-[3H] Nicotine Binding by the Enantiomers of Nicotine, Nomicotine and Anatoxin- a in Membranes and Solubilized Preparations of Different Brain Regions of Rat. Arch. Pharm. 1993, 348, 28-34.
50. Arneric, S. P.; Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Anderson, D. J.; Raszkiewicz, J. L.; Hughes, M.; Cadman, E. D.; Adams, P.; Garvey, D. S.; Wasicak, J.; Williams, M. ABT-418: A Novel Cholinergic Ligand with Cognition Enhancing and Anxiolytic Activity: I. In Vitro Characterization. J. Pharmacol. Exp. Ther., in press
51. Decker, M. W.; Brioni, J. P.; Sullivan, J. P.; Buckley, M. J.; Sullivan, J. P.; Radek, R. J.; Raszkiewicz, J. L.; Kang, C. H.; Kim, D. J. B.; Giardina, W. J.; Wasicak, J.; Garvey, D. S.; Williams, M.; Arneric, S. P. ABT-418: A Novel Cholinergic Ligand with Cognition Enhancing and Anxiolytic Activity: II. In Vivo Characterization. J. Pharmacol. Exp. Ther., in press